179 related articles for article (PubMed ID: 16135467)
1. Prospective multicenter validation of the independent prognostic value of the mitotic activity index in lymph node-negative breast cancer patients younger than 55 years.
Baak JP; van Diest PJ; Voorhorst FJ; van der Wall E; Beex LV; Vermorken JB; Janssen EA
J Clin Oncol; 2005 Sep; 23(25):5993-6001. PubMed ID: 16135467
[TBL] [Abstract][Full Text] [Related]
2. In lymph node-negative invasive breast carcinomas, specific chromosomal aberrations are strongly associated with high mitotic activity and predict outcome more accurately than grade, tumour diameter, and oestrogen receptor.
Janssen EA; Baak JP; Guervós MA; van Diest PJ; Jiwa M; Hermsen MA
J Pathol; 2003 Dec; 201(4):555-61. PubMed ID: 14648658
[TBL] [Abstract][Full Text] [Related]
3. Multivariate prognostic evaluation of the mitotic activity index and fibrotic focus in node-negative invasive breast cancers.
Baak JP; Colpaert CG; van Diest PJ; Janssen E; van Diermen B; Albernaz E; Vermeulen PB; Van Marck EA
Eur J Cancer; 2005 Sep; 41(14):2093-101. PubMed ID: 16153819
[TBL] [Abstract][Full Text] [Related]
4. Mitotic activity and bone marrow micrometastases have independent prognostic value in node positive breast cancer patients.
Gilje B; Nordgård O; Tjensvoll K; Janssen EA; Søiland H; Smaaland R; Baak JP
Breast Cancer Res Treat; 2011 Jul; 128(1):137-46. PubMed ID: 21476002
[TBL] [Abstract][Full Text] [Related]
5. The prognostic value of proliferation in lymph-node-negative breast cancer patients is age dependent.
Baak JP; van Diest PJ; Voorhorst FJ; van der Wall E; Beex LV; Vermorken JB; Janssen EA; Gudlaugsson E;
Eur J Cancer; 2007 Feb; 43(3):527-35. PubMed ID: 17110097
[TBL] [Abstract][Full Text] [Related]
6. Proliferation is the strongest prognosticator in node-negative breast cancer: significance, error sources, alternatives and comparison with molecular prognostic markers.
Baak JP; Gudlaugsson E; Skaland I; Guo LH; Klos J; Lende TH; Søiland H; Janssen EA; Zur Hausen A
Breast Cancer Res Treat; 2009 May; 115(2):241-54. PubMed ID: 18665447
[TBL] [Abstract][Full Text] [Related]
7. Prospective multicenter comparison of proliferation and other prognostic factors in lymph node negative lobular invasive breast cancer.
Gudlaugsson E; Skaland I; Janssen EA; van Diest PJ; Voorhorst FJ; Kjellevold K; zur Hausen A; Baak JP
Breast Cancer Res Treat; 2010 May; 121(1):35-40. PubMed ID: 19568929
[TBL] [Abstract][Full Text] [Related]
8. Volume corrected mitotic index (M/V index), mitotic activity index (MAI), and histological grading in breast cancer.
Lipponen PK; Collan Y; Eskelinen MJ
Int Surg; 1991; 76(4):245-9. PubMed ID: 1663917
[TBL] [Abstract][Full Text] [Related]
9. Lack of prognostic significance of histological grade in node-negative invasive breast carcinoma.
Younes M; Laucirica R
Clin Cancer Res; 1997 Apr; 3(4):601-4. PubMed ID: 9815726
[TBL] [Abstract][Full Text] [Related]
10. 'Blind' multicenter evaluation of the prognostic value of DNA image cytometric and morphometric features in invasive breast cancer.
Theissig F; Baak JP; Schuurmans L; Haroske G; Meyer W; Kunze KD
Anal Cell Pathol; 1996 Mar; 10(2):85-99. PubMed ID: 8721952
[TBL] [Abstract][Full Text] [Related]
11. Gene expression of estrogen receptor, progesterone receptor and microtubule-associated protein Tau in high-risk early breast cancer: a quest for molecular predictors of treatment benefit in the context of a Hellenic Cooperative Oncology Group trial.
Pentheroudakis G; Kalogeras KT; Wirtz RM; Grimani I; Zografos G; Gogas H; Stropp U; Pectasides D; Skarlos D; Hennig G; Samantas E; Bafaloukos D; Papakostas P; Kalofonos HP; Pavlidis N; Fountzilas G
Breast Cancer Res Treat; 2009 Jul; 116(1):131-43. PubMed ID: 18668363
[TBL] [Abstract][Full Text] [Related]
12. Prognostic differences of World Health Organization-assessed mitotic activity index and mitotic impression by quick scanning in invasive ductal breast cancer patients younger than 55 years.
Skaland I; van Diest PJ; Janssen EA; Gudlaugsson E; Baak JP
Hum Pathol; 2008 Apr; 39(4):584-90. PubMed ID: 18291440
[TBL] [Abstract][Full Text] [Related]
13. Prognostic factors of early distant recurrence in hormone receptor-positive, postmenopausal breast cancer patients receiving adjuvant tamoxifen therapy: results of a retrospective analysis.
Debled M; MacGrogan G; Brouste V; Mathoulin-Pelissier S; Durand M; Mauriac L
Cancer; 2007 Jun; 109(11):2197-204. PubMed ID: 17450590
[TBL] [Abstract][Full Text] [Related]
14. In primary breast cancer the mitotic activity yields similar prognostic information as the histological grade: a study with long-term follow-up.
Bult P; Manders P; Straatman HM; Tjan-Heijnen VC; Beex LV; Hendriks J; Leer JW; Verbeek AL; Holland R
Breast Cancer Res Treat; 2010 Jul; 122(1):77-86. PubMed ID: 19760038
[TBL] [Abstract][Full Text] [Related]
15. Proliferation in African breast cancer: biology and prognostication in nigerian breast cancer material.
Ikpatt OF; Kuopio T; Collan Y
Mod Pathol; 2002 Aug; 15(8):783-9. PubMed ID: 12181262
[TBL] [Abstract][Full Text] [Related]
16. Prognostic significance of bcl-2 expression in stage III breast cancer patients who had received doxorubicin and cyclophosphamide followed by paclitaxel as adjuvant chemotherapy.
Lee KH; Im SA; Oh DY; Lee SH; Chie EK; Han W; Kim DW; Kim TY; Park IA; Noh DY; Heo DS; Ha SW; Bang YJ
BMC Cancer; 2007 Apr; 7():63. PubMed ID: 17430582
[TBL] [Abstract][Full Text] [Related]
17. Supraclavicular radiation for breast cancer does not increase the 10-year risk of stroke.
Woodward WA; Giordano SH; Duan Z; Hortobagyi GN; Buchholz TA
Cancer; 2006 Jun; 106(12):2556-62. PubMed ID: 16691617
[TBL] [Abstract][Full Text] [Related]
18. The prognostic value of MARCKS-like 1 in lymph node-negative breast cancer.
Jonsdottir K; Zhang H; Jhagroe D; Skaland I; Slewa A; Björkblom B; Coffey ET; Gudlaugsson E; Smaaland R; Janssen EA; Baak JP
Breast Cancer Res Treat; 2012 Sep; 135(2):381-90. PubMed ID: 22772381
[TBL] [Abstract][Full Text] [Related]
19. Identifying good prognosis group of breast cancer patients with 1-3 positive axillary nodes for adjuvant cyclophosphamide, methotrexate and 5-fluorouracil (CMF) chemotherapy.
Lin YC; Chen SC; Chang HK; Hsueh S; Tsai CS; Lo YF; Hwang TL; Chen MF
Jpn J Clin Oncol; 2005 Sep; 35(9):514-9. PubMed ID: 16199422
[TBL] [Abstract][Full Text] [Related]
20. Validation of 70-gene prognosis signature in node-negative breast cancer.
Bueno-de-Mesquita JM; Linn SC; Keijzer R; Wesseling J; Nuyten DS; van Krimpen C; Meijers C; de Graaf PW; Bos MM; Hart AA; Rutgers EJ; Peterse JL; Halfwerk H; de Groot R; Pronk A; Floore AN; Glas AM; Van't Veer LJ; van de Vijver MJ
Breast Cancer Res Treat; 2009 Oct; 117(3):483-95. PubMed ID: 18819002
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
